Bio-based world newsSynthetic biology breakthrough could ignite cheaper biofuel production.Bio-based world newsThe benefit of using synthetic biology is down to the fact that it leverages genome sequences of organisms, such as bacteria and yeast, and r… Continue reading
LancasterOnline |
Lancaster County family wants gene therapy approved for rare disease causing blindness
LancasterOnline “While we are still learning about the long-term effects, recent studies in a host of rare disorders have been encouraging as a viable and long-lasting therapy, a possible game-changer for rare disease,” wrote Karlla W. Brigatti, the clinic’s genetic … |
Reuters |
GSK wins US shingles vaccine approval, UK nod for gene therapy
Reuters It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease — a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene … GSK gets approvals for ‘bubble boy’ syndrome gene therapy in UK and shingles vaccine in USProactive Investors UK |
Proactive Investors UK |
GSK wins US shingles vaccine approval, UK nod for gene therapy
Reuters It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease — a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene … GSK gets approvals for ‘bubble boy’ syndrome gene therapy in UK and shingles vaccine in USProactive Investors UK |
Proactive Investors UK |
GSK gets approvals for ‘bubble boy’ syndrome gene therapy in UK and shingles vaccine in US
Proactive Investors UK Britain’s National Institute for Health and Care Excellence (NICE) said in draft guidance that the Strimvelis gene therapy improves overall survival in patients with adenosine deaminase deficiency, or ADA-SCID, compared with standard stem cell … |
Labiotech.eu (blog) |
The German CEO Pushing for an Immunotherapy to Treat Cancer and HIV
Labiotech.eu (blog) Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company’s unique immunotherapy against both cancer and HIV. Mariola Söhngen has an outstanding track record as an entrepreneur and leader in biotech and … |